Plain-English translation of NCT06602843 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment approach for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer). The study combines chemotherapy and immunotherapy before surgery, followed by radiation therapy and immunotherapy after surgery. Researchers want to see if this combination approach helps patients live longer and controls their cancer better than the standard treatment of chemotherapy and radiation before surgery.
Advanced esophageal cancer is very difficult to treat, and current standard approaches don't work well enough for many patients. This trial explores whether adding immunotherapy—a newer type of treatment that helps your immune system fight cancer—to the traditional approach could improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would first receive chemotherapy combined with immunotherapy to shrink your tumor before surgery. Then you would have surgery to remove the cancerous portion of your esophagus. After surgery, you would receive radiation therapy along with additional immunotherapy. The research team would monitor you closely with imaging scans and blood tests throughout treatment to track how well the cancer responds and how you tolerate the therapy.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Sponsor
Anhui Provincial Hospital
Enrollment target
~70 participants
Started
January 2024
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.